摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-c]噻嗪-4-酮 | 175202-91-2

中文名称
3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-c]噻嗪-4-酮
中文别名
3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-C]噻嗪-4-酮
英文名称
1-methyl-2,2,4-trioxo-1,2,3,4-tetrahydro-2λ6-benzo[c][1,2]thiazine-7-carboxylic acid methyl ester
英文别名
1-methyl-2,2,4-trioxo-1,2,3,4-tetrahydro-2λ6-benzo[c] [1,2]thiazine-7-carboxylic acid methyl ester;1-methyl-2,2,4-trioxo-1,2,3,4-tetrahydro-2-λ6-benzo[c][1,2]thiazine-7-carboxylic acid methyl ester;Methyl 1-methyl-2,2,4-trioxo-1,2,3,4-tetrahydro-2,1-benzothiazine-7-carboxylate;methyl 1-methyl-2,2,4-trioxo-2λ6,1-benzothiazine-7-carboxylate
3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-c]噻嗪-4-酮化学式
CAS
175202-91-2
化学式
C11H11NO5S
mdl
——
分子量
269.278
InChiKey
UEHJSPSKPQORNS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    466.0±55.0 °C(Predicted)
  • 密度:
    1.430±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    89.1
  • 氢给体数:
    0
  • 氢受体数:
    6

安全信息

  • 危险品标志:
    Xi

SDS

SDS:4dd01f0c6bc25b67268dafafaa2e9153
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-c]噻嗪-4-酮 在 sodium tetrahydroborate 、 甲基磺酰氯三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 2.5h, 生成 Methyl 1-methyl-2,2-dioxo-2lambda6,1-benzothiazine-7-carboxylate
    参考文献:
    名称:
    作为CRTH2抑制剂的吲哚类化合物
    摘要:
    本申请公开了如式(I)所示的作为CRTH2抑制剂的吲哚类化合物或其药学上可接受的盐,以及其在治疗与CRTH2受体相关的疾病中的应用。
    公开号:
    CN107987072B
  • 作为产物:
    描述:
    Dimethyl 2-[methyl(methylsulfonyl)amino]benzene-1,4-dicarboxylate 在 sodium hydride 作用下, 以 四氢呋喃 、 mineral oil 为溶剂, 反应 3.0h, 以5 g的产率得到3,4-二氢-2,2-二氧代-7-甲氧基羰基-1-甲基苯并[2,1-c]噻嗪-4-酮
    参考文献:
    名称:
    作为CRTH2抑制剂的吲哚类化合物
    摘要:
    本申请公开了如式(I)所示的作为CRTH2抑制剂的吲哚类化合物或其药学上可接受的盐,以及其在治疗与CRTH2受体相关的疾病中的应用。
    公开号:
    CN107987072B
点击查看最新优质反应信息

文献信息

  • Piperazine derivatives and methods of use
    申请人:Chen J. Jian
    公开号:US20050014749A1
    公开(公告)日:2005-01-20
    Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物,以及用于预防和治疗涉及疼痛、炎症等疾病或其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法,以及在这类方法中有用的中间体。
  • [EN] CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ<br/>[FR] DERIVES AMINES CYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES LIES A L'INFLAMMATION INDUITS PAR LA BRADYKININE
    申请人:AMGEN INC
    公开号:WO2004092164A1
    公开(公告)日:2004-10-28
    Compounds of formula (I) are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation mediated by Bradykinin. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes wherein q, t, R, Ra, Rb, Rc and R2 are as defined herein.
    公式(I)的化合物对于治疗疼痛和疾病,如由炎症介导的疾病,具有有效性。该发明涵盖了新型化合物,其药学上可接受的衍生物,药物组合物以及用于预防和治疗涉及疼痛、由Bradykinin介导的炎症等疾病和其他疾病或病况的方法。该发明还涉及制备此类化合物的方法,以及在这些方法中有用的中间体,其中q、t、R、Ra、Rb、Rc和R2如本文所定义。
  • Cyclic amine derivatives and methods of use
    申请人:Groneberg D. Robert
    公开号:US20050234044A1
    公开(公告)日:2005-10-20
    Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    选定的化合物对于治疗疼痛和疾病,如炎症介导的疾病,具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物,药物组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他疾病或病症的方法。该发明还涉及制备这些化合物的过程,以及在这些过程中有用的中间体。
  • Compounds and methods of use
    申请人:Groneberg D. Robert
    公开号:US20050124654A1
    公开(公告)日:2005-06-09
    Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明包括新颖的化合物、类似物、前药和其药学上可接受的衍生物、制药组合物以及预防和治疗涉及疼痛、炎症等疾病和其他疾病或病况的方法。该发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。
  • COMPOUNDS AND METHODS OF USE
    申请人:Groneberg Robert D.
    公开号:US20090048224A1
    公开(公告)日:2009-02-19
    Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    所选化合物可有效治疗疼痛和疾病,如炎症介导的疾病。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物、制药组合物以及预防和治疗涉及疼痛、炎症等疾病和其他病症或状况的方法。该发明还涉及制备此类化合物的方法以及在这些过程中有用的中间体。
查看更多